- Home
- INVH vs JAZZ Comparison
INVH vs JAZZ Comparison
Compare INVH & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INVH | JAZZ |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 15.6B |
| IPO Year | 2016 | 2007 |
Fundamental Metrics
Financial Performance| Metric | INVH | JAZZ |
|---|---|---|
| Price | $29.78 | $253.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 14 |
| Target Price | $32.50 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 4.0M | 659.5K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | ★ 29.73 | N/A |
| EPS | 0.26 | ★ 4.43 |
| Revenue | ★ $2,729,296,000.00 | $1,618,693,000.00 |
| Revenue This Year | $2.92 | $6.22 |
| Revenue Next Year | $2.43 | $7.68 |
| P/E Ratio | $113.23 | ★ $57.53 |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $24.25 | $105.00 |
| 52 Week High | $32.05 | $255.20 |
Technical Indicators
Market Signals| Indicator | INVH | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 50.03 | 62.37 |
| Support Level | $29.29 | $222.49 |
| Resistance Level | $30.12 | N/A |
| Average True Range (ATR) | 0.52 | 7.52 |
| MACD | -0.09 | 0.84 |
| Stochastic Oscillator | 30.80 | 86.30 |
Price Performance
Historical ComparisonAbout INVH Invitation Homes Inc.
Invitation Homes owns a portfolio of over 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 17 target markets that feature high employment and household formation growth with over 70% of the portfolio in the Western US and Florida; 15 of the 17 markets featuring average rents lower than homeownership costs.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.